NCT04080245View on ClinicalTrials.gov

Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions
Influenza, Human
Interventions
BIOLOGICAL

Treatment Group Live Attenuated Flu Vaccine (LAIV)

We will administer LAIV once as a vaccine prime and IIV once as a vaccine boost with serial weekly blood draws for a month to validate a biomarker of LAIV efficacy.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT04080245 - Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV) | Biotech Hunter | Biotech Hunter